Aeterna Zentaris Inc. (AEZS) Stock Rating Lowered by Zacks Investment Research
Aeterna Zentaris Inc. (NASDAQ:AEZS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
AEZS has been the topic of several other reports. Maxim Group restated a “buy” rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a report on Wednesday, June 15th. Canaccord Genuity restated a “buy” rating and issued a $9.00 price objective on shares of Aeterna Zentaris in a report on Tuesday, August 23rd. Finally, HC Wainwright restated a “buy” rating on shares of Aeterna Zentaris in a report on Thursday, August 11th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/aeterna-zentaris-inc-aezs-stock-rating-lowered-by-zacks-investment-research.html
Aeterna Zentaris (NASDAQ:AEZS) traded up 3.89% during mid-day trading on Tuesday, hitting $3.47. 178,478 shares of the stock were exchanged. The company has a 50 day moving average of $3.51 and a 200 day moving average of $3.54. The firm’s market cap is $34.49 million. Aeterna Zentaris has a 12-month low of $2.60 and a 12-month high of $15.70.
Aeterna Zentaris (NASDAQ:AEZS) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative net margin of 5,871.45% and a negative return on equity of 241.78%. On average, equities analysts anticipate that Aeterna Zentaris will post ($2.61) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Aeterna Zentaris stock. Renaissance Technologies LLC raised its position in Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned approximately 8.17% of Aeterna Zentaris worth $1,716,000 at the end of the most recent reporting period. 8.28% of the stock is currently owned by hedge funds and other institutional investors.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.